← Leaderboards
Walter Acosta
Biostrategies, Lc
$3,031,644
Attributed
$9,802,178
Total exposure
9
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,802,178 · 9
By mechanism
R44$8,372,526 · 4
R43$1,429,652 · 5
Top collaborators
- Carole L. Cramer12 shared
- David Radin10 shared
- Tianhong Yang3 shared
- Alessandra D'Azzo2 shared
Most similar at Biostrategies, Lc
Same institution · by research overlap
- David Radin$3,550,799
- Tianhong Yang$821,265
Others in their field
Top investigators on “Organ”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lawrence Corey · Fred Hutchinson Cancer Center$451,040,128
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
OrganFamilyMouse ModelSmall Business Innovation Research GrantAffectMammalian CellLectinUptakeEnzymesTissuesPublic HealthIn VivoPharmaceutical PreparationsCellsInnovationHealth SystemMediatingBrainHuman GeneticsCostTechnologyPre-ClinicalPathologyBase
Grant awards (12)
Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme$1,500,000
R44 · FY2025 · NS · contact PI
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases$295,923
R43 · FY2023 · HD · contact PI
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS$390,497
R43 · FY2022 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$905,262
R44 · FY2021 · HD
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$1,144,737
R44 · FY2020 · HD
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease$293,232
R43 · FY2019 · HL
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,147,007
R44 · FY2018 · NS
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,071,897
R44 · FY2018 · NS
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme$225,000
R43 · FY2018 · AR
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease$1,366,586
R44 · FY2017 · NS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery$1,237,037
R44 · FY2017 · NS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization$225,000
R43 · FY2016 · HD